Event chart ABBOTT LABORATORIES |
|
|
Upcoming events on ABBOTT LABORATORIES |
|
10/19/22 | | Q3 2022 Earnings Release (Projected) |
01/25/23 | | FY 2022 Earnings Release (Projected) |
04/19/23 | | Q1 2023 Earnings Release (Projected) |
07/20/23 | | Interim 2023 Earnings Release (Projected) |
|
Past events on ABBOTT LABORATORIES |
|
07/20/22 | 09:00am | | Interim 2022 Earnings Call |
07/20/22 | 07:30am | | Interim 2022 Earnings Release |
07/14/22 | | Ex-dividend day for |
06/05/22 | | American Diabetes Association Scientific Conference |
04/29/22 | 10:00am | | Annual General Meeting |
04/27/22 | | Advanced Technologies & Treatments for Diabetes Congress |
04/20/22 | 09:00am | | Q1 2022 Earnings Call |
04/20/22 | 07:30am | | Q1 2022 Earnings Release |
04/13/22 | | Ex-dividend day for |
01/26/22 | 09:00am | | FY 2021 Earnings Call |
|
Past dividends on ABBOTT LABORATORIES |
|
07/14/22 | | Quarterly 0.47 USD |
04/13/22 | | Quarterly 0.47 USD |
01/13/22 | | Quarterly 0.47 USD |
10/14/21 | | Quarterly 0.45 USD |
07/14/21 | | Quarterly 0.45 USD |
04/14/21 | | Quarterly 0.45 USD |
01/14/21 | | Quarterly 0.45 USD |
10/14/20 | | Quarterly 0.36 USD |
07/14/20 | | Quarterly 0.36 USD |
04/14/20 | | Quarterly 0.36 USD |
|
|
Fiscal Period : December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
Sales M $ |
Released Forecast Spread | 27 390 27 194 0,72% | 30 578 30 652 -0,24% | 31 904 31 846 0,18% | 34 608 33 854 2,2% | 43 075 42 206 2,1% | 42 541 |
Operating income (EBITDA) M $ |
Released Forecast Spread | 7 022 6 968 0,78% | 9 833 7 757 27% | 8 188 8 266 -0,94% | 9 204 8 954 2,8% | 12 815 12 584 1,8% | 11 978 |
Operating profit (EBIT) M $ |
Released Forecast Spread | 5 976 6 010 -0,56% | 6 555 6 616 -0,91% | 7 110 7 149 -0,55% | 8 009 7 841 2,1% | 11 324 11 010 2,8% | 10 542 |
Pre-Tax Profit (EBT) M $ |
Released Forecast Spread | 2 231 3 867 -42% | 2 873 2 782 3,3% | 4 077 3 920 4,0% | 4 968 4 052 23% | 8 211 7 728 6,2% | 7 657 |
Net income M $ |
Released Forecast Spread | 353 1 805 -80% | 2 334 2 380 -1,9% | 3 687 3 655 0,87% | 4 471 4 415 1,3% | 7 071 6 738 4,9% | 6 855 |
EPS $ |
Released Forecast Spread | 0,20 1,00 -80% | 1,31 1,34 -2,5% | 2,06 2,10 -1,7% | 2,49 2,45 1,7% | 3,94 3,80 3,8% | 3,85 | Announcement Date | 01/24/2018 | 01/23/2019 | 01/22/2020 | 01/27/2021 | 01/26/2022 | - |
|
|
Fiscal Period : December | 2020 Q2 | 2020 Q3 | 2020 Q4 | 2021 Q1 | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 |
Sales M $ |
Released Forecast Spread | 7 328 6 853 6,9% | 8 853 8 531 3,8% | 10 701 9 935 7,7% | 10 456 10 675 -2,1% | 10 223 9 673 5,7% | 10 928 9 564 14% | 11 468 10 697 7,2% | 11 895 10 996 8,2% | 11 257 10 400 8,2% | 9 594 | 9 644 | 9 606 | 9 979 | 10 088 |
Operating income (EBITDA) M $ |
Released Forecast Spread | 1 587 1 107 43% | 2 303 2 300 0,11% | 3 464 3 241 6,9% | 3 265 2 997 9,0% | 2 918 2 661 9,7% | 3 369 2 404 40% | 3 263 2 954 10% | 4 247 3 434 24% | 2 762 | 2 316 | 2 320 | 2 516 | 2 706 | 2 747 |
Operating profit (EBIT) M $ |
Released Forecast Spread | 1 315 943 39% | 2 005 1 990 0,73% | 3 106 2 941 5,6% | 2 840 2 732 4,0% | 2 548 2 233 14% | 3 042 2 089 46% | 2 894 2 598 11% | 3 620 3 058 18% | 2 985 2 394 25% | 1 941 | 1 967 | 2 186 | 2 338 | 2 442 |
Pre-Tax Profit (EBT) M $ |
Released Forecast Spread |
|
|
| 2 043 1 932 5,8% |
|
|
|
|
|
|
|
|
|
|
Net income M $ |
Released Forecast Spread | 537 169 217% | 1 232 1 098 12% | 2 158 1 927 12% | 1 793 1 800 -0,39% | 1 189 1 096 8,5% | 2 100 1 137 85% | 1 989 1 555 28% | 2 447 2 277 7,5% | 2 018 1 433 41% | 1 093 | 1 104 | 1 292 | 1 441 | 1 481 |
EPS $ |
Released Forecast Spread | 0,30 0,12 147% | 0,69 0,62 11% | 1,20 1,07 12% | 1,00 0,91 9,7% | 0,66 0,66 -0,69% | 1,17 0,67 74% | 1,11 0,89 24% | 1,37 1,22 12% | 1,14 0,79 44% | 0,63 | 0,63 | 0,76 | 0,85 | 0,88 | Announcement Date | 07/16/2020 | 10/21/2020 | 01/27/2021 | 04/20/2021 | 07/22/2021 | 10/20/2021 | 01/26/2022 | 04/20/2022 | 07/20/2022 | - | - | - | - | - | |
|
|
Upcoming sector events for ABBOTT LABORATORIES |
|
|
|
Past sector events for ABBOTT LABORATORIES |
|
|
|
|
|
|
Danone sends 1.3 million cans of Aptamil formula to U.S. amid shortage |
Net sales (Year) - Rate of surprise
EPS (Year) - Rate of surprise
Net sales (Quarter) - Rate of surprise
EPS (Quarter) - Rate of surprise
|